The FDA has released new draft guidance for monoclonal antibody drug testing, signaling a move away from animal testing towards human-based models such as computer simulations and organ-on-chip technology. This change follows concerns about the ethical implications and cost of using macaque monkeys in drug testing, as well as the failure rate of drugs tested on animals in clinical trials. Advocacy organizations have praised the FDA's decision as a step towards a more humane and scientifically sound approach to drug development.

Similar developments are taking place in the UK, where the science minister has announced a roadmap to phase out animal testing in favor of human-centered approaches. This shift towards alternative testing methods has been welcomed by advocates, who see it as a significant step towards a more compassionate future for scientific research. The move signifies a growing recognition of the limitations of animal testing and a commitment to finding more effective and ethical ways to ensure the safety and efficacy of medical treatments.